IGC Pharma
9 hedge funds and large institutions have $223K invested in IGC Pharma in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
114% more capital invested
Capital invested by funds: $104K → $223K (+$119K)
50% more funds holding
Funds holding: 6 → 9 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$112K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$30.3K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$19.7K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.12K |
| 5 |
Bank of New York Mellon
New York
|
+$4.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$30.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
1
Virtu KCG Holdings
New York
| $115K | +$112K | +251,493 | +844% |
|
|
PAM
2
Panagora Asset Management
Boston,
Massachusetts
| $38K | +$19.7K | +44,195 | +90% |
|
|
3
UBS Group
Zurich,
Switzerland
| $29K | +$30.3K | +67,837 | +1,746% |
|
4
Creative Planning
Overland Park,
Kansas
| $21K | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| $10K | -$30.2K | -67,680 | -74% |
|
|
6
Bank of New York Mellon
New York
| $4K | +$4.46K | +10,000 | New |
|
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $4K | +$5.12K | +11,475 | New |
|
|
LTFS
8
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
9
Acadian Asset Management
Boston,
Massachusetts
| $1K | +$1.28K | +2,876 | New |
|
IGC Hedge Fund Activity: Q2 2017 in Review
9 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q2 2017, worth a combined $223K — up 114% from $104K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IGC positions and 0 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Virtu KCG Holdings, adding an estimated $112K. The largest seller was Citadel Advisors, cutting an estimated $30.2K.
- 9 institutional investors held IGC Pharma (IGC) as of Q2 2017, up from 6 in Q1 2017.
- Funds reported $223K of IGC Pharma stock for Q2 2017, up 114% quarter-over-quarter.
- 3 funds opened new IGC Pharma positions in Q2 2017 and 0 closed out, a net change of +3 holders.
- The largest IGC Pharma buyer in Q2 2017 was Virtu KCG Holdings, an estimated $112K added.
- The largest IGC Pharma seller in Q2 2017 was Citadel Advisors, an estimated $30.2K sold.
Based on aggregated 13F filings for Q2 2017.